Resmed CFO Sandercock sells $224k in stock

CFO Brett Sandercock sold 1,000 ResMed shares on April 1, 2026 at $224.31 for $224,310 under a pre-arranged Rule 10b5-1 plan, leaving him with 83,495 shares. ResMed reported FQ2 2026 EPS $2.81 vs. $2.73 consensus and revenue of $1.4B in line with expectations; organic revenue growth accelerated to 8% in the quarter (from 7% in Q1). RBC raised its price target from $311 to $314 and KeyBanc from $299 to $302 while other brokers maintained Holds; the company has increased its dividend for 14 consecutive years.

Analysis

ResMed’s core advantage is the annuity-like consumables and remote-monitoring bundle that creates high visibility for revenue beyond device shipments; that makes near-term beats less informative than changes in device attach rates and CPAP adherence trends. A small sequential uptick in organic growth can meaningfully compress the time it takes for software and mask-sales margins to scale into operating leverage, but the converse is also true — a slip in adherence or a reimbursement change would show up first in consumables trends before device revenue.

Second-order competitive dynamics favor players with integrated software ecosystems: vendors who can monetize data (adherence coaching, telemonitoring) capture higher lifetime value than device-only peers, increasing the bar for new entrants and low-cost competitors. Supply-chain effects matter — mask and filter tooling constraints are a hidden lever; modest CAPEX to expand consumable capacity can drive outsized revenue durability without large incremental R&D risk.

Key tail risks are regulatory/recall shocks to the CPAP category and Medicare reimbursement resets; both can flip a multi-year growth story into a shrinking aftermarket within 2–4 quarters. Near-term volatility will be dominated by survey-driven usage readouts and CMS policy chatter, while the multi-year upside depends on continued penetration of remote-monitoring and bundled care with sleep clinics.

Key Decisions for Investors

• Long RMD (6–12 month): initiate a core long position sized to 5–7% of equity portfolio, averaging in on any pullbacks. Hedge 25% of notional by shorting a broad medical-equipment/healthcare ETF to isolate CPAP-specific execution risk; target asymmetric upside of ~2:1 vs downside capped by dividend and buyback support.
• Options overlay (9–12 month): buy a call spread to express directional upside while limiting premium paid — allocate up to 1.5% of portfolio; max loss = premium, potential return 2–4x if adoption and software monetization accelerate.
• Yield harvest (0–3 month): sell covered calls against part of the position to monetize a relatively stable cash flow profile and the upcoming periods of muted fundamental revisions; use strikes ~5–10% out of the money to keep upside optionality.
• Event pair trade (0–3 months): long RMD / short PHG (Philips Respironics) sized 60/40 to bias long exposure to resilient consumables vs regulatory-exposed device risk. Keep size tactical and set stop-loss at 10% adverse move to limit recall/regulatory blow-up risk.